Comparative analysis of clinicopathologic features, treatment, and survival of Asian women with a breast cancer diagnosis residing in the United States

Min Yi(First Affiliated Hospital of Xi'an Jiaotong University), Kelly K. Hunt(The University of Texas MD Anderson Cancer Center), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Yu Ren(Chongqing University), Xu Li(Chinese University of Hong Kong), Peijun Liu(The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture), Jianjun He(Hebei Medical University), Khazi M. Nayeemuddin(The University of Texas MD Anderson Cancer Center)
Cancer
January 3, 2012
10.1002/cncr.27399
Cited by 37

Related Papers

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
|Nature|2015|2.9k
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
|The Lancet|2020|1.1k
Whole-genome analysis informs breast cancer response to aromatase inhibition
|Nature|2012|1k
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
|Journal of Clinical Oncology|2017|411